Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down Following Weak Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) shares gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $49.26, but opened at $46.52. Travere Therapeutics shares last traded at $45.7810, with a volume of 1,225,620 shares traded.

The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.45). Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%. The firm had revenue of $224.56 million during the quarter, compared to analysts’ expectations of $195.29 million. During the same period last year, the business earned $0.28 earnings per share. The business’s revenue was up 36.2% on a year-over-year basis.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 36.2% year over year to approximately $224.6 million, exceeding the $195.3 million analyst consensus. FILSPARI net product sales reached $200 million, reflecting continued expansion in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Travere Therapeutics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: A valuation analysis argued that Travere could be about 34% undervalued following its third-quarter loss, potentially supporting the stock if investors place greater weight on the company’s revenue growth and commercial execution. Why Travere Therapeutics Could Be 34% Undervalued

Analysts Set New Price Targets

TVTX has been the topic of several recent research reports. Guggenheim raised their target price on Travere Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a report on Thursday, September 24th. Citigroup upped their price target on Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group increased their price objective on Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wedbush reissued an “outperform” rating and issued a $76.00 price objective on shares of Travere Therapeutics in a research note on Tuesday, September 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $67.00 target price on shares of Travere Therapeutics in a report on Tuesday, September 22nd. Ten research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $69.50.

Insider Buying and Selling

In other news, insider William Rote sold 112,850 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $63.33, for a total transaction of $7,146,790.50. Following the sale, the insider owned 98,197 shares of the company’s stock, valued at approximately $6,218,816.01. This trade represents a 53.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jula Inrig sold 44,674 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $2,784,977.16. Following the sale, the executive vice president owned 100,491 shares in the company, valued at approximately $6,264,608.94. This represents a 30.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,294,029 shares of company stock worth $79,454,261. 4.44% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors have recently bought and sold shares of TVTX. S&CO Inc. acquired a new stake in Travere Therapeutics during the second quarter valued at approximately $3,181,000. Artia Global Partners LP bought a new stake in shares of Travere Therapeutics in the 2nd quarter valued at approximately $19,260,000. Elmind Capital LP acquired a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $16,622,606. Bank of America Corp DE acquired a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $259,527,000. Finally, Jupiter Topco LLC acquired a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $643,299,000.

Travere Therapeutics Price Performance

The company has a debt-to-equity ratio of 24.58, a quick ratio of 3.99 and a current ratio of 4.05. The firm has a market cap of $4.38 billion, a P/E ratio of -99.88 and a beta of 1.13. The company has a 50-day moving average of $58.73 and a 200 day moving average of $46.56.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.